



ATTORNEY'S DOCKET NO: M0765/7034 (HCL/MAT)


THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael Laposata
Serial No: 09/758,099
Filed: January 10, 2001
For: METHODS FOR MONITORING ALCOHOL CONSUMPTION
Examiner: Not yet assigned
Art Unit: 3736

RECEIVED
AUG 09 2001
RECEIVED
APR 23 2001
TECHNOLOGY CENTER R3700

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 17 day of April, 2001.


Maryanne Trevisan

Commissioner for Patents
Washington, D.C. 20231

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

REMARKS

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 
Helen C. Lockhart (Reg. No. 39,248)
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. M0765/7034 (HCL/MAT)
Dated: April 17, 2001
x05/10/01



3736

ATTORNEY'S DOCKET NO: M0765/7034 (HCL/MAT)

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael Laposata
Serial No: 09/758,099
Filed: January 10, 2001
For: METHODS FOR MONITORING ALCOHOL CONSUMPTION
Examiner: Not yet assigned
Art Unit: 3736

RECEIVED

AUG 09 2001

TC 1700

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 17 day of April, 2001.


Maryanne Trevisan

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement/1449/references cited
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,


By: 
Helen C. Lockhart (Reg. No. 39,248)
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. M0765/7034 (HCL/MAT)
Dated: April 17, 2001
x5/10/01

RECEIVED

APR 23 2001

TECHNOLOGY CENTER R3700



RECEIVED

AUG 09 2001

ATTY. DOCKET NO.: M0765/7034

APPLICATION NO.: 09/758,889

FILING DATE: January 10, 2001

APPLICANT: Michael Laposata

GROUP ART UNIT: 3736

EXAMINER: not yet assigned

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YY
		Number	Kind Code		
	A1	5,952,235		Bearer	September 14, 1999
	A2	5,399,731		Wimmer, et al.	March 21, 1995
	A3	5,399,730		Koupchinov, et al.	March 21, 1995
	A4	5,126,271		Harasymiw, et al.	June 30, 1992
	A5	4,797,233		Zinnen, et al.,	January 10, 1989
	A6	4,721,584		Arai, et al.	January 26, 1988
	A7	4,608,202		Lepper, et al.	August 26, 1986
	A8	4,334,540		Preti, et al.	June 15, 1982
	A9	5,515,847		Braig, et al.	May 14, 1996


FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
		ACHESON, "Factors contributing to the accelerated clearance of theophylline and antipyrine in adults with exocrine pancreatic disease", <i>Clin. Sci.</i> , 76:377-85 (1989)		
		ALERYANI, et al., "Fatty acid ethyl ester synthase, an enzyme for nonoxidative ethanol metabolism, is present in serum after liver and pancreatic injury", <i>Clin. Chem.</i> , 42(1):24-27 (1996)		
		BEARER, et al., "Fatty acid ethyl esters in peripheral blood", <i>Dysmorphology & Teratology</i> , #395, page 68A ABSTRACT		
		BEARER, et al., "Fetal alcohol syndrome and fatty acid ethyl esters", <i>Pediatric Research</i> , , <i>Pediatric Res.</i> 31(5):492-495 (1992)		
		BERNHARDT, et al., "Purification of fatty acid ethyl esters by solid-phase extraction and high-performance liquid chromatography", <i>J. Chromatography</i> , 675:189-196 (1996)		
		BIRD, et al., "The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum", <i>Alcoholism: Clin Exper. Res.</i> , 21(4):602-605 (1997)		
		BIRD, et al., "Binding of ethyl oleate to low density lipoprotein, phospholipid vesicles, and albumin: a ¹³ C NMR study", <i>J. Lipid Res.</i> , 37:1449-1458 (1996)		

		BIRD, et al., "Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells", <i>Alcoholism: Clinical and Experimental Research</i> , 19(5):1265-1270 (1995)		
		BJORNTOP, et al., "Alcohol consumption and synthesis of ethyl esters of fatty acids in adipose tissue", <i>J. Intern. Med (England)</i> , 228(6):557-62 (1990) ABSTRACT		
		CHEN, et al., "Comparison of the susceptibility to oxidation of lipoproteins isolated by ultracentrifugation and precepitation", <i>Eleventh Annual Mid-Atlantic Lipid Research Symposium</i> March 10-12, (1999) ABSTRACT		
		DAN, et al., "Ethyl palmitate and ethyl oleate are the predominant fatty acid ethyl esters in the blood after ethanol ingestion and their synthesis is differentially influenced by the extracellular concentrations of their corresponding fatty acids", <i>Alcoholism: Clinical and Experimental Research</i> , 21(2):286292 (1997)		
		DOYLE, et al., "Fatty acid esters in the blood as markers for ethanol intake", <i>JAMA</i> , 276(14):1152-1156 (1996)		
		DOYLE, et al., "Fatty acid ethyl esters are present in human serum after ethanol ingestion", <i>J.Lipid Res.</i> , 35:428-437 (1994)		
		FIELD, "Microsatellite instability in squamous cell carcinoma of the head and neck", <i>Br. J. Cancer</i> , 71:1065-1069 (1995) ABSTRACT		
		GARNERO, "Decreased bone turnover in oral contraceptive users", <i>Bone</i> , 16:499-503 (1995) ABSTRACT		
		GIRRE, "Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorozoxazone pharmacokinetics", <i>Biochem. Pharmacol.</i> , 47:1503-8 (1994) ABSTRACT		
		GORSKI, et al., "Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics", <i>Alcoholism: Clinical and Experimental Research</i> , 20(2):268-274 (1996)		
		HEITH, et al., "Fatty acid ethyl ester synthase catalyzes the esterification of ethanol to cocaine", <i>Biochem. Biophys. Res. Comm.</i> , 208(2):549-554 (1995)		
		HUNGUND, et al., "Formation of fatty acid ethyl esters and their relationship to the development of tolerance to ethanol in chronic alcohol treated mice", <i>J. Neurochem.</i> , 48 (1987) S11		
		KABAKIBI, et al., "Fatty acid ethyl esters and HepG2 cells: intracellular synthesis and release from the cells", <i>J. Lipid Res.</i> , 38:15681582 (1998)		
		KALUZNY, et al., "Rapid separation of lipid classes in high yield and purity using bonded phase column", <i>J. Lipid Res.</i> , 26:135-140 (1985)		
		KAPLAN, L.M., "Leptin-insulin interactions: an adipocyte-islet axis?", <i>Eleventh Annual Mid-Atlantic Lipid Research Symposium</i> March 10-12, (1999) ABSTRACT		
		KOECHLING, "Family history of alcoholism and mediation of alcohol intake by catalase: further evidence for catalase as a marker of the propensity to ingest alcohol", <i>Alcohol. Clin. Exp. Res.</i> , 19:1096-104 (1995) ABSTRACT		
		LANGE, et al., "Identification of fatty acid ethyl esters as products of rabbit myocardial ethanol metabolism", <i>J. Biol. Chem.</i> , 256:12968-73 (1981) ABSTRACT		
		LAPOSATA, E., "Fatty acid ethyl esters-metabolism and clinical detection", NIH Project No. R29AA08034; Gopher-CRISP Database, FY 90, ABSTRACT		
		LAPOSATA, et al., "Fatty acid ethyl esters in adipose tissue. A laboratory marker for alcohol-related death", <i>Arch. Pathol. Lab. Med.</i> , 113(7):762-6 (1989) ABSTRACT		
		LAPOSATA, et al., "Fatty acid ethyl esters: non-oxidative metabolites of ethanol", <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 52:87-91 (1995)		
		LAPOSATA, et al., "Metabolism of ethanol by human brain to fatty acid ethyl esters", <i>J. Biol. Chem.</i> , 262:4653-7 (1987) ABSTRACT		
		LAPOSATA, et al., "Synthesis and degradation of fatty acid ethyl esters by cultured hepatoma cells exposed to ethanol", <i>J. Biol. Chem.</i> , 265:9688-93 (1990) ABSTRACT		
		LAPOSATA, M., "Fatty acid ethyl esters: ethanol metabolites which mediate ethanol-induced organ damage and serve as markers of ethanol intake", <i>Prog. Lipid Res.</i> , 37(5):307-316 (1998)		
		LAPOSATA, M., "Fatty acid ethyl esters: nonoxidative metabolites of ethanol", <i>Addiction Biology</i> , 3:5-14 (1998)		
		LAPOSATA, M., "Fatty acid ethyl esters: short-term and long-term serum markers of ethanol intake", <i>Clin. Chem.</i> , 43:8(B):1527-1534 (1997)		
		LAPOSATA, M., "Fatty acids: a brief primer on the classifications of fatty acids and their influence on the serum cholesterol level", <i>Clin. Lab. Rev.</i> , 7(3):10-13 (1999)		
		MUSSHOFF, et al., "Determination of biological markers for alcohol abuse", <i>J. Chromatogr. B. Biomed. Sci. Appln.</i> , 713(1):245-64 (1998) ABSTRACT		



		OSHITA, "Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C", <i>Hepatology</i> 20:1115-1120 (1994) ABSTRACT		
		PHILLIPS, "Localization of genes affecting alcohol consumption", <i>Alcohol Clin. Exp. Res.</i> , 18:931-941 (1994) ABSTRACT		
		PILANE, et al., "Increased monocyte adhesion ICAM-1 and VCAM-1 expression and NFκB activation in human endothelial cells by cholesterol", <i>Eleventh Annual Mid-Atlantic Lipid Research Symposium</i> March 10-12, (1999) ABSTRACT		
		POIKOLAINEN "Correlations between biological markers and alcohol intake as measured by diary and questionnaire in men", <i>J. Stud. Alcohol</i> , 46:383-7 (1985) ABSTRACT		
		REFAAI, et al., "Fatty acid ethyl esters are postmortem markers of antemortem ethanol intake", March 10-12, Mid-Atlantic Lipid Research Symposium - Poster Session		
		SAGHIR, et al., "Rapid in vivo hydrolysis of fatty acid ethyl esters, toxic nonoxidative ethanol metabolites", <i>Am J Physiol.</i> , 273:G184-90 (1997)		
		SODERBERG, et al., "Refinement of an assay for fatty acid ethyl ester in serum and plasma as an indicator of ethanol intake"" Poster Session; Mid-Atlantic Lipid Symposium: Atlantic City N.J., March 1999		
		STIBLER, "Transferrin phenotype and level of carbohydrate-deficient transferrin in healthy individuals", <i>Alcohol Clin. Exp. Res.</i> , 12:450-3 (1988) ABSTRACT		
		SZCZEPIONIOWSKI, et al., "Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis", <i>Gastroenterology</i> , 108:515-522 (1995)		
		WERNER, et al., "Pancreatic injury in rats induced by fatty acid ethyl ester, a nonoxidative metabolite of alcohol", <i>Gastroenterology</i> , 113:286-294 (1997)		
		WRIGHT, et al., "Nonoxidative ethanol metabolism in human leukocytes: detection of fatty acid ethyl ester synthase activity"" <i>Biochem. Biophys. Res. Comm.</i> , 142(3):979-985 (1987) ABSTRACT		
		YANG, et al., "Assessment of ethanol intake: antemortem and postmortem analysis", <i>Clin. Lab. Rev.</i> , 7(3):1-9 (1999)		
		ZHENG, et al., "Effects of acute and chronic ethanol exposure on fatty acid ethyl ester synthases in mouse cerebellar membranes", <i>Addict. Biol.</i> , 3(1):85-90 (1998)		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]